Sensus Healthcare names Michael Sardano as chief commercial officer
Leadership Appointment: Sensus Healthcare's president, Michael Sardano, has been appointed as the chief commercial officer, a newly created role.
Expanded Responsibilities: In his new position, Sardano will oversee the company's global sales, marketing, and commercial strategy for its SRT technologies and Sentinel software.
Recent Milestone: This appointment follows a significant reimbursement milestone from the Centers for Medicare & Medicaid Services.
New CPT Codes: The milestone includes the establishment of current procedural terminology codes for the use of superficial radiotherapy in treating non-melanoma skin cancer.
Trade with 70% Backtested Accuracy
Analyst Views on SRTS
About SRTS
About the author
Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections
Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.
Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.
Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.
Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026
Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.
Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.
CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.
Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.
Sensus Healthcare Reports the Death of Director Bill McCall
Passing of Bill McCall: Sensus Healthcare announces the passing of longtime friend and Director William "Bill" McCall, who played a crucial role in the company's development since 2009 and served on the Board since 2015.
Legacy and Contributions: Bill McCall was recognized for his financial acumen and leadership, significantly contributing to Sensus Healthcare's mission to provide patient-centric therapies, and was remembered as a trusted advisor and loyal friend.
Professional Background: McCall had a distinguished career in financial advisory and portfolio management, holding leadership positions at various firms and serving on multiple boards, including Cherokee Farm Partners.
Charitable Endeavors: Beyond his professional achievements, McCall was known for his charitable work, supporting educational and community organizations throughout Tennessee, leaving a lasting impact on both Sensus Healthcare and the community.
Reminder for Sensus Healthcare Investors: Bragar Eagel & Squire Urges Stockholders to Reach Out About Ongoing Investigation
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Sensus Healthcare, Inc. (NASDAQ:SRTS) for possible violations of federal securities laws following a significant drop in stock price after disappointing financial results.
Contact Information: Investors who suffered losses from Sensus stock are encouraged to contact partners Brandon Walker or Marion Passmore for legal advice and to discuss their options without any cost or obligation.
Sensus Healthcare, Inc. (SRTS) Outperforms Market Returns: Key Insights to Consider
Stock Performance: Sensus Healthcare, Inc. (SRTS) saw a 2.26% increase to $3.17, outperforming the S&P 500's 0.26% gain, but has declined 8.55% over the past month, significantly underperforming the Medical sector and the S&P 500.
Earnings Outlook: The upcoming earnings report is anticipated to show an EPS of -$0.12, a drastic decline from the previous year, with revenue expected to drop by 47.51% to $4.64 million; the Zacks Rank currently rates SRTS as a #5 (Strong Sell).
INVESTOR NOTICE: Pomerantz Law Firm Probes Allegations for Sensus Healthcare, Inc. Investors - SRTS
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Sensus Healthcare, Inc. and its officers/directors, urging affected investors to contact them.
Financial Performance and Stock Impact: Sensus reported disappointing Q2 2025 results, with a GAAP earnings-per-share of -$0.06 and a revenue decline of 20.7%, leading to a significant drop in stock price by 35.32% following the announcement.
Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections
Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.
Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.
Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.
Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026
Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.
Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.
CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.
Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.
Sensus Healthcare Reports the Death of Director Bill McCall
Passing of Bill McCall: Sensus Healthcare announces the passing of longtime friend and Director William "Bill" McCall, who played a crucial role in the company's development since 2009 and served on the Board since 2015.
Legacy and Contributions: Bill McCall was recognized for his financial acumen and leadership, significantly contributing to Sensus Healthcare's mission to provide patient-centric therapies, and was remembered as a trusted advisor and loyal friend.
Professional Background: McCall had a distinguished career in financial advisory and portfolio management, holding leadership positions at various firms and serving on multiple boards, including Cherokee Farm Partners.
Charitable Endeavors: Beyond his professional achievements, McCall was known for his charitable work, supporting educational and community organizations throughout Tennessee, leaving a lasting impact on both Sensus Healthcare and the community.
Reminder for Sensus Healthcare Investors: Bragar Eagel & Squire Urges Stockholders to Reach Out About Ongoing Investigation
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Sensus Healthcare, Inc. (NASDAQ:SRTS) for possible violations of federal securities laws following a significant drop in stock price after disappointing financial results.
Contact Information: Investors who suffered losses from Sensus stock are encouraged to contact partners Brandon Walker or Marion Passmore for legal advice and to discuss their options without any cost or obligation.
Sensus Healthcare, Inc. (SRTS) Outperforms Market Returns: Key Insights to Consider
Stock Performance: Sensus Healthcare, Inc. (SRTS) saw a 2.26% increase to $3.17, outperforming the S&P 500's 0.26% gain, but has declined 8.55% over the past month, significantly underperforming the Medical sector and the S&P 500.
Earnings Outlook: The upcoming earnings report is anticipated to show an EPS of -$0.12, a drastic decline from the previous year, with revenue expected to drop by 47.51% to $4.64 million; the Zacks Rank currently rates SRTS as a #5 (Strong Sell).
INVESTOR NOTICE: Pomerantz Law Firm Probes Allegations for Sensus Healthcare, Inc. Investors - SRTS
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Sensus Healthcare, Inc. and its officers/directors, urging affected investors to contact them.
Financial Performance and Stock Impact: Sensus reported disappointing Q2 2025 results, with a GAAP earnings-per-share of -$0.06 and a revenue decline of 20.7%, leading to a significant drop in stock price by 35.32% following the announcement.
